CALL - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 01:43:29 2024-07-17 pm EDT | ||
| 54.84 EUR | -4.87% |
|
| Current month | +3.56% | ||
| 1 month | +9.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 54.84 | -4.87% |
| 24-07-16 | 57.65 | -0.88% |
| 24-07-15 | 58.16 | +0.31% |
| 24-07-12 | 57.98 | +2.95% |
| 24-07-11 | 56.32 | -2.12% |
Delayed Quote Deutsche Boerse AG
Last update July 17, 2024 at 01:43 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6E9Z |
| ISIN | DE000VU6E9Z6 |
| Date issued | 2023-04-18 |
| Strike | 318.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 59.32 € |
|---|---|
| Lowest since issue | 7.35 € |
| Spread | 0.03 € |
| Spread % | 0.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Certificates
- Certificat
